Bretylium
As of the edition of 20 October 2026, Bretylium is a small molecule: marketed, first approved in 1982 (US); acts on SLC6A2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Bretylol
- First approved
- 1 January 1982 (US)
- Approvals on record
- 14 in 1 region
- Holder of the most recent approval
- Baxter Healthcare; 5 holders in all
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Bretylium.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | P23975 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Abbott | Acquired holder and Later holder | 1986 to now |
| B. Braun Medical | Later holder | 1986 to now |
| Baxter Healthcare | Later holder | 1989 to now |
| Pfizer | Acquired holder | 2008 to now |
| Dupont Merck | Earlier holder |